ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are 1) Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. 2) IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
This is not a financial advice!
Upcoming catalysts in 2024.
Ultra low floater - Shs Float of 1.6M
Short Float 12.09%
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
SL under 0.8
TP approx. 3.0
Most info on the chart.
Trade carefully!
This is not a financial advice!
Upcoming catalysts in 2024.
Ultra low floater - Shs Float of 1.6M
Short Float 12.09%
We need to stay in a bullish overal sentiment of the market. If we see a corretion, this play might doesn't work.
SL under 0.8
TP approx. 3.0
Most info on the chart.
Trade carefully!
註釋
booom what a timing
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
Join Discord channel:
whop.com/marketplace/contingent-traders/
contingenttrader.com/
whop.com/marketplace/contingent-traders/
contingenttrader.com/
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。